In EMPA-KIDNEY, in which over half of the participants did not have diabetes, SGLT-2 inhibition was shown to have consistent relative benefits across the spectrum of eGFR, including among people with eGFR < 20 mL/min/1.73m2 (Fig. 4) [3]. Here, SLC5A2 is linked to diabetes mellitus.